AHL Investment Management Inc. Acquires 550 Shares of Pfizer Inc. (NYSE:PFE)

AHL Investment Management Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 0.6% in the 4th quarter, HoldingsChannel reports. The firm owned 85,437 shares of the biopharmaceutical company’s stock after buying an additional 550 shares during the quarter. Pfizer comprises approximately 1.6% of AHL Investment Management Inc.’s holdings, making the stock its 22nd largest holding. AHL Investment Management Inc.’s holdings in Pfizer were worth $2,267,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of the business. Wells Trecaso Financial Group LLC raised its holdings in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company’s stock worth $416,000 after purchasing an additional 350 shares in the last quarter. Washington Trust Advisors Inc. raised its stake in shares of Pfizer by 0.7% during the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company’s stock worth $1,424,000 after acquiring an additional 360 shares in the last quarter. Cullen Investment Group LTD. lifted its position in Pfizer by 0.9% during the third quarter. Cullen Investment Group LTD. now owns 42,677 shares of the biopharmaceutical company’s stock valued at $1,235,000 after acquiring an additional 377 shares during the last quarter. PSI Advisors LLC lifted its position in Pfizer by 1.4% during the fourth quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company’s stock valued at $738,000 after acquiring an additional 385 shares during the last quarter. Finally, MidWestOne Financial Group Inc. boosted its stake in Pfizer by 1.5% in the second quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock valued at $742,000 after acquiring an additional 386 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $26.30 on Monday. The company has a market capitalization of $149.06 billion, a P/E ratio of 35.55, a P/E/G ratio of 0.64 and a beta of 0.64. The business’s 50-day moving average is $26.08 and its two-hundred day moving average is $27.99. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the company earned ($0.17) EPS. The business’s revenue was up 31.2% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.54%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 227.03%.

Analyst Ratings Changes

Several brokerages have recently commented on PFE. Citigroup started coverage on Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price objective for the company. Evercore ISI raised Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. UBS Group dropped their price target on Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 8th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 price objective on shares of Pfizer in a research report on Tuesday, December 10th. Finally, Sanford C. Bernstein initiated coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a “market perform” rating and a $32.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $32.00.

Insider Activity

In other Pfizer news, Director Scott Gottlieb purchased 1,000 shares of the stock in a transaction that occurred on Wednesday, October 30th. The shares were purchased at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at $282,400. The trade was a 11.11 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.